Livagen: Uses, Benefits & Research

What is Livagen?

Livagen (Ala-Glu-Asp-Leu) is a synthetic tetrapeptide developed at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia by Professor Vladimir Khavinson. It belongs to the “Khavinson peptides” family and is marketed primarily as a hepatoprotective agent — a compound intended to protect and support liver function. At 4 amino acids and 430 Da, it is an ultrashort synthetic peptide.

Livagen is a synthetic compound and should not be confused with bovine tissue extracts like Thymalin — these are fundamentally different compound types despite originating from the same research institute.

Mechanism of Action

The proposed mechanism of action for Livagen remains entirely theoretical and has not been validated in human studies:

1. Hepatocyte protection — Livagen is proposed to protect liver cells from toxin-induced damage, though the specific protective pathway is undefined
2. Liver regeneration — Research suggests the peptide may support hepatocyte proliferation, but receptor targets remain unknown
3. Detoxification support — Some proponents suggest Livagen enhances liver detoxification pathways, though no molecular targets have been identified

No published study has demonstrated how a 4-amino-acid peptide could achieve pharmacologically meaningful hepatoprotection, or what receptors or enzymes it acts upon.

Clinical Evidence

Human Studies

No human clinical data exists for Livagen. Specifically:

• Zero published randomized controlled trials
• Zero PubMed-indexed human studies
• No registered Western clinical trials (ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP)
• No pharmacokinetic studies in humans
• No validated human dosing data

Preclinical Evidence

Available animal data is reported secondhand from Russian-language sources and has not been independently verified in PubMed-indexed publications:

Model	Species	Reported Finding	Status
Liver damage	Rat	Protection from toxins	Unverified
Liver regeneration	Rat	Hepatocyte proliferation	Unverified
Liver enzymes	Rat	Normalization of ALT/AST	Unverified

All preclinical findings originate from the Khavinson Institute or affiliated researchers. Independent replication by Western laboratories has not been published.

Drug Interactions & Contraindications

No formal drug interaction studies have been conducted. All interactions listed are theoretical, inferred from the proposed mechanism of action. Preclinical data indicates potential overlap with hepatotoxic drugs, statins, and CYP450 enzyme modulators. Livagen should be avoided during pregnancy and breastfeeding, in individuals with active liver failure, and during concurrent hepatotoxic drug therapy, due to the complete absence of safety data.

Safety & Side Effects

The safety profile of Livagen is entirely unknown. No Phase I safety trials have been conducted, and no published adverse event reports exist — not because the compound is proven safe, but because no systematic human safety data has been collected.

Theoretical safety concerns include:

• Unknown toxicity at any dose in humans
• Liver enzyme alteration that could mask or exacerbate existing liver conditions
• Drug metabolism effects that could alter clearance of other medications
• Unknown drug interactions — no interaction studies have been performed

Honest Bottom Line

Livagen is a synthetic tetrapeptide with zero published human clinical evidence. The hepatoprotective claims are based entirely on unverified Russian-language animal studies from the research group that developed the compound. No independent Western laboratory has replicated these findings.

Individuals considering Livagen for liver support should be aware that established hepatoprotectants — including silymarin (milk thistle extract) and N-acetylcysteine — have considerably more human evidence, though their efficacy for certain indications is also debated. There is no human safety or efficacy data for Livagen, no FDA approval, and no clear regulatory pathway toward clinical use.